Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus–Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial TF was detectable in 75.4% of baseline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results